Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Bilimsel Danışma Kurulu | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | İletişim  
2019, Cilt 33, Sayı 1, Sayfa(lar) 047-050   
AFATINIB TREATMENT IN SQUAMOUS CELL LUNG CARCINOMA WITH EXON 19 DELETION: CASE REPORT
Berna KÖMÜRCÜOĞLU1, Eylem YILDIRIM1, Pınar GÜRSOY2, Deniz NART3, Murat AKYOL4
1SBÜ İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi SUAM, Göğüs Hastalıkları Kliniği, İzmir, Türkiye
2Ege Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalı, İzmir, Türkiye
3Ege Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, İzmir, Türkiye
4SBÜ İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi SUAM, Tıbbi Onkoloji Kliniği, İzmir, Türkiye
Keywords: Afatinib, EGFR, lung cancer, squamous cell lung carcinoma

A 66-year-old male with a history of smoking was admitted with the symptoms of cough, malaise, weight loss and arm pain. The patient's chest radiography showed a homogeneous density in the left lower zone. Thoracic computed tomography revealed a mass lesion with a lobulated contour in the left lower lobe. Endobronchial biopsy and transbronchial needle aspiration biopsy were reported as squamous cell lung carcinoma. Brain, bone and liver metastases were detected in the staging. Patient was staged as stage 4 squamous cell lung carcinoma- multiple distant metastasis sites M1b. Cranial radiotherapy was planned for brain metastasis. The patient did not accept the systemic chemotherapy. As genetic analysis of pathological preparations showed that exon 19 deletion was positive, the patient was initiated on afatinib treatment. In the 3rd and 6th months of the treatment, the patient's primary mass and brain metastasis were markedly regressed. The patient did not have any serious side effects except intermittent dizziness and fatigue. However, he died of sudden loss of consciousness in the 8th month of the treatment.